RVXCF (OTC) is a cross-listing of RVX.TO (TSX). Showing primary listing data.
RVX.TO
Resverlogix Corp.
1W: +5.0%
1M: -4.5%
3M: +10.5%
YTD: +0.0%
1Y: +110.0%
3Y: -25.0%
5Y: -89.2%
C$0.10 ($0.08)
-0.01 (-4.55%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market CapC$30.2M ($21.8M)
52W Range0.04-0.3
Volume31,415
Avg Volume34,283
Beta1.09
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODonald J. McCaffrey
Employees19
SectorHealthcare
IndustryBiotechnology
IPO Date2004-05-07
Websiteresverlogix.com
4820 Richard Road SW
Calgary, AB T3E 6L1
CA
Calgary, AB T3E 6L1
CA
14032549252
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found